Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium.
OBJECTIVE
The purpose was to report a case of elevated intraocular vascular endothelial growth factor (VEGF) levels in a 2-year-old boy with stage 4 Coats disease.


METHODS
Interventional case report.


METHODS
A 2-year-old boy with severe Coats disease and complex retinal detachment refractory to surgical intervention underwent two injections of intravitreal pegaptanib sodium in his right eye 8 weeks apart.


RESULTS
After intravitreal injection there was a marked reduction in VEGF (908 to 167 pg/ml) levels and improvement of exudation, hemorrhage, and nearly complete reattachment of his retina within 3 weeks of treatment. The patient remains stable 6 months post-treatment.


CONCLUSIONS
Coats disease may have a component of dysregulation of VEGF-mediated angiogenesis as evidenced by elevated levels in this patient.
Sun
Young
Y
Department of Ophthalmology, Stanford University, 300 Pasteur Drive, Room A-157, Stanford, CA 94305, USA.
Jain
Atul
A
Moshfeghi
Darius M
DM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D002675:Child, Preschool; D006801:Humans; D007267:Injections; D008297:Male; D012164:Retinal Diseases / Q000188:drug therapy* / Q000378:metabolism; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology; D013684:Telangiectasis / Q000188:drug therapy* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib